论文部分内容阅读
血管紧张素转化酶抑制剂是 80年代初期开始应用于临床的一类重要降压药 ,随后其适应症逐步扩展到心力衰竭 (已证实能明显降低死亡率 )、心肌梗死 (预防心室重构 )、心肌炎 (扩张血管 ,改善冠脉循环并清除自由基 )和非心血管疾病如糖尿病相关性与非相关性肾病等。血管紧张素Ⅱ受体阻滞剂是 90年代中期应用于临床的肾素 血管紧张素系统抑制药 ,由于其直接阻断肾素 血管紧张素系统的效应分子血管紧张素Ⅱ的作用 ,因此 ,其抑制肾素 血管紧张素系统的作用更为强大。本文综述近两年来血管紧张素转化酶抑制剂和血管紧张素Ⅱ受体阻滞剂在非心、肾血管系统疾病中的应用研究进展 ,重点概述了在消化系统疾病中的应用。
Angiotensin-converting enzyme inhibitors are an important class of antihypertensive drugs that have been used clinically in the early 1980s and have subsequently been extended to include heart failure (which has been shown to significantly reduce mortality), myocardial infarction (to prevent ventricular remodeling) , Myocarditis (dilation of blood vessels, improvement of coronary circulation and clearance of free radicals) and non-cardiovascular diseases such as diabetes-related and non-related kidney disease. Angiotensin II receptor blocker is a clinical renin-angiotensin system inhibitor used in the mid-1990s. Because it directly blocks the effector molecule angiotensin II of the renin-angiotensin system, Inhibition of renin angiotensin system is more powerful. This review summarizes the application of angiotensin converting enzyme inhibitors and angiotensin Ⅱ receptor blockers in noncardiac and renal vascular diseases in recent two years, and summarizes the application of angiotensin converting enzyme inhibitors in digestive diseases.